small-logo
ProfessionalsCapabilitiesInsights & NewsCareersLocations
About UsAlumniOpportunity & InclusionPro BonoCorporate Social Responsibility
Stay Connected:
facebookinstagramlinkedintwitteryoutube
Site Search
  • Professionals (646)
  • Capabilities (81)
  • Experience (162)
  • Insights & News (5,844)
  • Other Results (88)

Professionals 646 results

Mats G. Carlston
Mats G. Carlston
Partner
  • New York
Email
+1 212-294-6696
vCard

Partner

  • New York
Krishnan Padmanabhan
Krishnan Padmanabhan
Partner
  • New York, 
  • Los Angeles, 
  • Silicon Valley
Email
+1 212-294-3564
vCard

Partner

  • New York
  • Los Angeles
  • Silicon Valley
Reid Smith
Reid Smith
Partner
  • Chicago
Email
+1 312-558-7241
vCard

Partner

  • Chicago
View All Professionals

Capabilities 81 results

Industry

Medical Devices

The medical device industry is currently undergoing monumental change—from supply chain challenges to disruptive technologies and economic fluctuations. To pave the way for a more accessible and innovative health care landscape—including advances in wearables, implants, diagnostics, mobility, drug delivery—the evolving and expansive medical device industry faces wide-ranging legal needs. Clients in this sector can tap the remarkable depth and breadth of our sector-focused and skilled attorneys in the U.S. and abroad. Our Health Care & Life Sciences Industry Group engages clients at all points in the product development life cycle to provide sound advice and practical solutions regardless of the client’s size or the complexity of their need. We help clients navigate today’s complex regulatory landscape, defend products and reputations in the face of high-profile product liability and mass tort claims, protect innovative intellectual property (IP), and leverage cross-border experience to advise on commercial transactions....Read more

Industry

Financial Crimes Compliance

Winston’s financial crimes compliance lawyers have been providing regulatory compliance counseling and enforcement services related to the Bank Secrecy Act (BSA), the Anti-Money Laundering Act of 2020 (AML), and countering the financing of terrorism (CFT) policy for decades. We also have experience with international AML matters, including in the EU and with respect to Financial Actions Task Force (FATF) recommendations....Read more

Industry

Artificial Intelligence (AI)

Experience 162 results

Experience

|

September 8, 2025

Winston Wins Ninth Circuit Reversal and Class Certification in Swimmers’ Antitrust Case, Securing a Global-Impact Settlement with World Aquatics

Winston represents a class of professional swimmers alleging World Aquatics (WA) violated antitrust laws by blocking their participation in the competing  International Swimming League. After WA won summary judgment, Winston successfully appealed, arguing the court applied improper antitrust standards and wrongly denied certification of a damages class. In September 2024, the Ninth Circuit reversed both rulings, reviving all claims and issuing a landmark ruling on the possible application of the per se rule or quick look review to sports-associations rules. Am Law awarded Winston “Litigator of the Week” Runner-Up recognition for the win. In November 2024, the Ninth Circuit denied rehearing. In April 2025, the district court certified a damages class....Read more

Experience

|

August 19, 2025

Winston Advised Ellipsis Onshore Holdings in the Acquisition of Oil and Gas Non-Operated Assets in the Permian Basin of Texas and New Mexico

Winston advised Ellipsis U.S. Onshore Holdings LLC, a portfolio company of the Westlawn Group, in connection with the acquisition of high-quality, non-operated working interests in the Permian Basin of Texas and New Mexico—adding approximately 4,000 barrels of oil equivalent per day in net production and over 600 gross remaining drilling locations. This strategic transaction strengthens Ellipsis’ Delaware Basin footprint and supports its strategy of scaling through high-margin, low-cost assets....Read more

Experience

|

July 17, 2025

D. Boral Capital Closes US$15M Robot Consulting IPO

Winston & Strawn LLP represented D. Boral Capital LLC and Craft Capital Management LLC in connection with the US$15M initial public offering of American Depositary Shares (ADSs) of Robot Consulting Co., Ltd. The offering consisted of 3,750,000 ADSs priced at $4.00 per ADS, and the company’s ADSs began trading on the Nasdaq Capital Market under the ticker symbol “LAWR” on July 17, 2025....Read more
View All Experience

Insights & News 5,844 results

Sponsorship

|

October 6, 2025

Winston Hosts the 2025 Inside PEVC inBrazil Forum

Winston & Strawn’s New York office is proud to host the 2025 Inside PEVC inBrazil Forum. Organized by the Brazilian Private Equity and Venture Capital Association (ABVCAP), the event brings together 100+ private equity and venture capital industry leaders to discuss the investment climate in Brazil. ...Read more

Client Alert

|

October 6, 2025

|

1 Min Read

California Limits Contractor Retention to Five Percent

Starting in 2026, California will cap retention in private construction contracts at 5%, matching public works standards. The rule excludes non-mixed-use residential projects under four stories and applies across all contractor-subcontractor levels. Lower retention rates for direct contractors will extend to subcontractors. Advocates say that the cap will ease financial strain, especially for smaller firms. Owners may respond with stricter bonding requirements, potentially raising construction costs due to reduced protection against non-performance.

Winston will continue to monitor developments and provide updates as they become available. Please contact your Winston relationship partner should you have any questions or to request further information.

Client Alert

|

October 3, 2025

|

4 Min Read

Debanking Developments: New Regulatory Scrutiny Coming After Trump Executive Order

In this alert, Winston’s Financial Services Industry Group examines the latest developments in regulatory scrutiny of “debanking,” with a particular focus on recent actions following a Trump administration executive order.

View All Insights & News

Other Results 88 results

Law Glossary

What Is the Standard for the FDA to Grant a Generic Drug License?

An Abbreviated New Drug Application (ANDA) must contain evidence that the proposed generic drug product is bioequivalent to the reference drug....Read more

Law Glossary

What Is the Approval Process for Generic Drugs?

Approval for generic drugs are governed by the Hatch-Waxman Act. The Hatch-Waxman Act provides the framework for an applicant to demonstrate that its proposed generic product is bioequivalent to the brand-name drug....Read more

Law Glossary

What Is a Generic Drug?

Generic drugs are typically small, chemically synthesized molecules—that is, they have relatively low molecular weights, frequently less than 1000 daltons and usually between 300 and 700 daltons. Biosimilars, on the other hand, are typically substantially larger in molecular weight than small molecule drugs. For example, a monoclonal antibody—a typical biosimilar drug—generally has a molecular weight in excess of 150,000 daltons. In contrast, aspirin—a typical small molecule drug—has a molecular weight of 180 daltons....Read more
Logo
facebookinstagramlinkedintwitteryoutube

Copyright © 2025. Winston & Strawn LLP

AlumniCorporate Transparency Act Task ForceDEI Compliance Task ForceEqual Rights AmendmentLaw GlossaryThe Oval UpdateWinston MinutePrivacy PolicyCookie PolicyFraud & Scam AlertsNoticesSubscribeAttorney Advertising